Efficacy And Response RatesThe number of confirmed responses increased from 5 to 10 among 20 evaluable patients, demonstrating continued superiority over chemotherapy's 35% overall response rate.
Pipeline DevelopmentThe company is planning to disclose additional data and initiate multiple studies, indicating active development and potential future advancements in their pipeline.
Safety ProfileZelenectide pevedotin continued to show a more favorable safety and tolerability profile vs. Padcev in the combination setting with lower Grade 3+ treatment-related skin reactions.